Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PCBM | ISIN: US0144421072 | Ticker-Symbol: 0Z2
Tradegate
23.04.25
21:56 Uhr
1,050 Euro
+0,020
+1,94 %
1-Jahres-Chart
ALECTOR INC Chart 1 Jahr
5-Tage-Chart
ALECTOR INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0101,02012:44
1,0101,02012:46

Aktuelle News zur ALECTOR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.03.Alector, Inc.: Alector Provides Executive Leadership Update229--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
10.03.Alector, Inc. - 8-K, Current Report2
26.02.Alector, Inc.: Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update141Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226...
► Artikel lesen
26.02.Alector, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.02.Alector, Inc. - 10-K, Annual Report-
26.02.Alector, Inc. - 8-K, Current Report-
ALECTOR Aktie jetzt für 0€ handeln
25.02.Alector Q4 2024 Earnings Preview1
13.01.Alector, Inc.: Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025128Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated...
► Artikel lesen
10.01.AbbVie terminates Alector collaboration agreement12
10.01.Alector, Inc. - 8-K, Current Report-
04.12.24Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts6
04.12.24Alector downgraded to Underperform at BofA after Alzheimer's trial miss3
26.11.24Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce14
26.11.24Alector turns to layoffs as Alzheimer's drug fails1
26.11.24Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 233
25.11.24Alector drops 31% as Alzheimer's candidate fails in phase 2 trial4
25.11.24Alector stoppt Alzheimer-Studie nach Verfehlen des Hauptziels4
25.11.24Alector halts Alzheimer's trial as drug fails key goal1
25.11.24Alector halts Alzheimer's trial after missing primary endpoint1
25.11.24Alector, Inc.: Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update160SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1